JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB76009

Anti-B MyB (phospho T487) antibody [EPR2204Y]

5

(1 Review)

|

(27 Publications)

Rabbit Recombinant Monoclonal B MyB phospho T487 antibody. Suitable for IHC-P, WB, ICC/IF, Dot, Flow Cyt (Intra) and reacts with Human, Transfected cell line - Human, Synthetic peptide samples. Cited in 27 publications.

View Alternative Names

BMYB, MYBL2, Myb-related protein B, B-Myb, Myb-like protein 2

8 Images
Immunocytochemistry/ Immunofluorescence - Anti-B MyB (phospho T487) antibody [EPR2204Y] (AB76009)
  • ICC/IF

Lab

Immunocytochemistry/ Immunofluorescence - Anti-B MyB (phospho T487) antibody [EPR2204Y] (AB76009)

Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HeLa (human cervix adenocarcinoma epithelial cell) cells labelling B MyB (phospho T487) with primary antibody anti-B MyB (phospho T487) (ab76009) at 1/1000 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed (ab150081) secondary antibody at 1/1000 dilution. Confocal image showing nuclear staining in HeLa cells and no staining in HeLa cells with Alkaline Phosphatase treatment 37℃ for 1 hour. Anti-alpha Tubulin antibody (DM1A) - Microtubule Marker (Alexa Fluor® 594) (ab195889) was used to counterstain tubulin at 1/200 dilution. The nuclear counter stain is DAPI (blue).

Flow Cytometry (Intracellular) - Anti-B MyB (phospho T487) antibody [EPR2204Y] (AB76009)
  • Flow Cyt (Intra)

Lab

Flow Cytometry (Intracellular) - Anti-B MyB (phospho T487) antibody [EPR2204Y] (AB76009)

Intracellular Flow Cytometry analysis of HeLa (human cervix adenocarcinoma) cells treated with Alkaline Phosphatase overnight (Left) and untreated HeLa cells (Right) labeling B MyB (phospho T487) with ab76009 at 1/1000 dilution (Red). Cells were fixed with 4% Paraformaldehyde and permeabilised with 0.1% Tween-20. A Goat anti rabbit IgG (Alexa Fluor® 488, ab150081) secondary antibody was used at 1/2000 dilution. Isotype control - Rabbit monoclonal IgG (ab172730) (Black). Unlabeled control - Cell without incubation with primary antibody and secondary antibody (Blue).

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-B MyB (phospho T487) antibody [EPR2204Y] (AB76009)
  • IHC-P

Lab

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-B MyB (phospho T487) antibody [EPR2204Y] (AB76009)

Immunohistochemistry analysis of paraffin-embedded Human colon cancer tissue sections labelling B MyB (phospho T487) with ab76009 at 1/8000 dilution. The section was incubated with ab76009 for 30 mins at room temperature. Rabbit specific IHC polymer detection kit HRP/DAB (ab209101) was used as the secondary antibody. Sections were counterstained with Hematoxylin. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins.
Nuclear staining on Human colon cancer tissue without alkaline phosphatase treatment (Image A); No signal was detected when tissues were treated with alkaline phosphatase (Image B). The immunostaining was performed on a Leica Biosystems BOND® RX instrument.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-B MyB (phospho T487) antibody [EPR2204Y] (AB76009)
  • IHC-P

Lab

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-B MyB (phospho T487) antibody [EPR2204Y] (AB76009)

Immunohistochemistry analysis of paraffin-embedded Human lung cancer tissue sections labelling B MyB (phospho T487) with ab76009 at 1/8000 dilution. The section was incubated with ab76009 for 30 mins at room temperature. Rabbit specific IHC polymer detection kit HRP/DAB (ab209101) was used as the secondary antibody. Sections were counterstained with Hematoxylin. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins.
Nuclear staining on Human lung cancer tissue without alkaline phosphatase treatment (Image A); No signal was detected when tissues were treated with alkaline phosphatase (Image B). The immunostaining was performed on a Leica Biosystems BOND® RX instrument.

Western blot - Anti-B MyB (phospho T487) antibody [EPR2204Y] (AB76009)
  • WB

Lab

Western blot - Anti-B MyB (phospho T487) antibody [EPR2204Y] (AB76009)

Blocking buffer and concentration : 5% NFDM/TBST Diluting buffer and concentration : 5% NFDM/TBST

Lanes 1 - 2:

Western blot - Anti-B MyB (phospho T487) antibody [EPR2204Y] - BSA and Azide free (<a href='/en-us/products/primary-antibodies/b-myb-phospho-t487-antibody-epr2204y-bsa-and-azide-free-ab232521'>ab232521</a>) at 1/1000 dilution

Lanes 1 - 2:

Western blot - Anti-B MyB (phospho T487) antibody [EPR2204Y] (ab76009) at 1/1000 dilution

Lane 1:

HeLa (Human cervix adenocarcinoma epithelial cell) nuclear fraction lysate at 15 µg

Lane 2:

HeLa nuclear fraction lysate treated with Alkaline Phosphatase for 1 hour at 15 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 79 kDa

Observed band size: 100 kDa

false

Exposure time: 120s

Western blot - Anti-B MyB (phospho T487) antibody [EPR2204Y] (AB76009)
  • WB

Lab

Western blot - Anti-B MyB (phospho T487) antibody [EPR2204Y] (AB76009)

Blocking buffer and concentration : 5% NFDM/TBST Diluting buffer and concentration : 5% NFDM/TBST

Lanes 1 - 2:

Western blot - Anti-B MyB (phospho T487) antibody [EPR2204Y] - BSA and Azide free (<a href='/en-us/products/primary-antibodies/b-myb-phospho-t487-antibody-epr2204y-bsa-and-azide-free-ab232521'>ab232521</a>) at 1/1000 dilution

Lanes 1 - 2:

Western blot - Anti-B MyB (phospho T487) antibody [EPR2204Y] (ab76009) at 1/1000 dilution

Lane 1:

HeLa (Human cervix adenocarcinoma epithelial cell) nuclear fraction lysate at 15 µg

Lane 2:

HeLa (Human cervix adenocarcinoma epithelial cell) without nuclear fraction lysate at 15 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 79 kDa

Observed band size: 100 kDa

false

Exposure time: 60s

Western blot - Anti-B MyB (phospho T487) antibody [EPR2204Y] (AB76009)
  • WB

Lab

Western blot - Anti-B MyB (phospho T487) antibody [EPR2204Y] (AB76009)

Blocking buffer and concentration : 5% NFDM/TBST Diluting buffer and concentration : 5% NFDM/TBST

Lanes 1 - 2:

Western blot - Anti-B MyB (phospho T487) antibody [EPR2204Y] - BSA and Azide free (<a href='/en-us/products/primary-antibodies/b-myb-phospho-t487-antibody-epr2204y-bsa-and-azide-free-ab232521'>ab232521</a>) at 1/1000 dilution

Lanes 1 - 2:

Western blot - Anti-B MyB (phospho T487) antibody [EPR2204Y] (ab76009) at 1/1000 dilution

Lane 1:

293T (Human embryonic kidney epithelial cell) transfected with empty vector (vector control), containing a myc-His-tag®, whole cell lysate at 20 µg

Lane 2:

293T transfected with human B MyB (WT) expression vector containing a myc-His-tag®, whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 79 kDa

Observed band size: 100 kDa

false

Exposure time: 20s

Dot Blot - Anti-B MyB (phospho T487) antibody [EPR2204Y] (AB76009)
  • Dot

Lab

Dot Blot - Anti-B MyB (phospho T487) antibody [EPR2204Y] (AB76009)

Dot blot analysis of B MyB (pT487) phospho peptide (lane 1) and B MyB non-phospho peptide (lane 2) with ab76009 at a 1/1000 dilution. Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) was used as the secondary antibody at a dilution of 1/20,000.
Blocking and dilution buffer : 5% NFDM/TBST
Exposure time : 3 minutes

  • Carrier free

    Anti-B MyB (phospho T487) antibody [EPR2204Y] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR2204Y

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

ICC/IF, WB, Flow Cyt (Intra), IHC-P, Dot

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "Dot" : {"fullname" : "Dot Blot", "shortname":"Dot"}, "FlowCytIntra" : {"fullname" : "Flow Cytometry (Intracellular)", "shortname":"Flow Cyt (Intra)"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/8000", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/1000", "ICCIF-species-notes": "<p></p>", "Dot-species-checked": "guaranteed", "Dot-species-dilution-info": "", "Dot-species-notes": "", "FlowCytIntra-species-checked": "testedAndGuaranteed", "FlowCytIntra-species-dilution-info": "1/1000", "FlowCytIntra-species-notes": "<p><a href='/en-us/products/primary-antibodies/rabbit-igg-monoclonal-epr25a-isotype-control-ab172730'>ab172730</a> - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.</p>" }, "Synthetic peptide": { "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "Dot-species-checked": "testedAndGuaranteed", "Dot-species-dilution-info": "1/1000", "Dot-species-notes": "<p></p>", "FlowCytIntra-species-checked": "notRecommended", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "" }, "Transfected cell line - Human": { "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "Dot-species-checked": "notRecommended", "Dot-species-dilution-info": "", "Dot-species-notes": "", "FlowCytIntra-species-checked": "notRecommended", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The B MyB protein also known as MYBL2 or B-MYB is a transcription factor involved in cell cycle regulation. It belongs to the MYB family of proteins and has a molecular weight of approximately 92 kDa. This protein is expressed in a range of tissues including proliferating cells. B MyB's activity as a transcription factor involves binding to specific DNA sequences to regulate gene expression essential for cell cycle progression particularly in the S phase where it plays a role in DNA replication and mitosis.
Biological function summary

MYBL2 participates in processes important for normal cell cycle and proliferation. It does not appear to form part of a larger protein complex but regulates genes necessary for cell division independently. B MyB significantly impacts the expression of factors that facilitate the transition from G1 to S phase of the cell cycle impacting cellular growth and replication. Its function ensures that the cells adequately prepare for DNA synthesis and subsequent mitotic division.

Pathways

Various cell cycle regulatory pathways rely on MYBL2 for their correct functioning. B MyB influences the G1/S phase transition and is associated with the E2F transcription factor pathway. In this context it regulates E2F target genes necessary for DNA synthesis. B MyB interacts with other proteins such as CDK2 and cyclins to orchestrate a synchronized cell cycle progression ensuring that cells divide correctly and effectively.

B MyB is frequently associated with cancer development and progression notably in contexts where there is rapid cell proliferation such as in breast cancer and leukemia. Dysregulation of MYBL2 expression or its downstream targets can lead to uncontrolled cell division thereby contributing to oncogenesis. It associates with proteins such as p53 a pivotal tumor suppressor where alterations in their pathways can lead to malignancy. Researchers evaluate B MyB's expression and activity as potential markers for cancer diagnosis and as targets for therapeutic intervention.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Transcription factor involved in the regulation of cell survival, proliferation, and differentiation. Transactivates the expression of the CLU gene.
See full target information MYBL2 phospho T487

Publications (27)

Recent publications for all applications. Explore the full list and refine your search

Cell regeneration (London, England) 13:24 PubMed39542983

2024

Identification of feature genes in intestinal epithelial cell types.

Applications

Unspecified application

Species

Unspecified reactive species

Ruoyu Lou,Wanlu Song,Shicheng Yu,Xiaodan Wang,Yuan Liu,Ye-Guang Chen,Yalong Wang

BMC medicine 21:68 PubMed36810084

2023

Nitazoxanide inhibits acetylated KLF5-induced bone metastasis by modulating KLF5 function in prostate cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Qingqing Huang,Mingcheng Liu,Duo Zhang,Bing-Biao Lin,Xing Fu,Zhiqian Zhang,Baotong Zhang,Jin-Tang Dong

Cell reports 41:111761 PubMed36476851

2022

Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation.

Applications

Unspecified application

Species

Unspecified reactive species

Martin F Orth,Didier Surdez,Tobias Faehling,Anna C Ehlers,Aruna Marchetto,Sandrine Grossetête,Richard Volckmann,Danny A Zwijnenburg,Julia S Gerke,Sakina Zaidi,Javier Alonso,Ana Sastre,Sylvain Baulande,Martin Sill,Florencia Cidre-Aranaz,Shunya Ohmura,Thomas Kirchner,Stefanie M Hauck,Eva Reischl,Melissa Gymrek,Stefan M Pfister,Konstantin Strauch,Jan Koster,Olivier Delattre,Thomas G P Grünewald

Frontiers in oncology 12:816070 PubMed35664780

2022

Downstream Regulatory Network of MYBL2 Mediating Its Oncogenic Role in Melanoma.

Applications

Unspecified application

Species

Unspecified reactive species

Feiliang Zhong,Jia Liu,Chang Gao,Tingting Chen,Bo Li

Nature 604:749-756 PubMed35444283

2022

CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.

Applications

Unspecified application

Species

Unspecified reactive species

David Gallo,Jordan T F Young,Jimmy Fourtounis,Giovanni Martino,Alejandro Álvarez-Quilón,Cynthia Bernier,Nicole M Duffy,Robert Papp,Anne Roulston,Rino Stocco,Janek Szychowski,Artur Veloso,Hunain Alam,Prasamit S Baruah,Alexanne Bonneau Fortin,Julian Bowlan,Natasha Chaudhary,Jessica Desjardins,Evelyne Dietrich,Sara Fournier,Chloe Fugère-Desjardins,Theo Goullet de Rugy,Marie-Eve Leclaire,Bingcan Liu,Vivek Bhaskaran,Yael Mamane,Henrique Melo,Olivier Nicolas,Akul Singhania,Rachel K Szilard,Ján Tkáč,Shou Yun Yin,Stephen J Morris,Michael Zinda,C Gary Marshall,Daniel Durocher

JCI insight 6: PubMed34622806

2021

p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia.

Applications

Unspecified application

Species

Unspecified reactive species

Na Man,Gloria Mas,Daniel L Karl,Jun Sun,Fan Liu,Qin Yang,Miguel Torres-Martin,Hidehiro Itonaga,Concepcion Martinez,Shi Chen,Ye Xu,Stephanie Duffort,Pierre-Jacques Hamard,Chuan Chen,Beth E Zucconi,Luisa Cimmino,Feng-Chun Yang,Mingjiang Xu,Philip A Cole,Maria E Figueroa,Stephen D Nimer

Frontiers in oncology 11:687208 PubMed34631522

2021

LINC00346 Sponges miR-30c-2-3p to Promote the Development of Lung Adenocarcinoma by Targeting MYBL2 and Regulating CELL CYCLE Signaling Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Qian Xu,Zhenwu Xu,Kai Zhu,Jinlan Lin,Bo Ye

Cancers 13: PubMed34359691

2021

Differential Effects of Combined ATR/WEE1 Inhibition in Cancer Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Gro Elise Rødland,Sissel Hauge,Grete Hasvold,Lilli T E Bay,Tine T H Raabe,Mrinal Joel,Randi G Syljuåsen

Cell death & disease 12:683 PubMed34234118

2021

A MYBL2 complex for RRM2 transactivation and the synthetic effect of MYBL2 knockdown with WEE1 inhibition against colorectal cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Qian Liu,Lijuan Guo,Hongyan Qi,Meng Lou,Rui Wang,Boning Hai,Kailun Xu,Lijun Zhu,Yongfeng Ding,Chen Li,Lingdan Xie,Jing Shen,Xueping Xiang,Jimin Shao

Cell reports 34:108808 PubMed33657372

2021

MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity.

Applications

Unspecified application

Species

Unspecified reactive species

Timothy B Branigan,David Kozono,Amy E Schade,Peter Deraska,Hembly G Rivas,Larissa Sambel,Hunter D Reavis,Geoffrey I Shapiro,Alan D D'Andrea,James A DeCaprio
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com